Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration
Collaboration focuses on developing novel protein replacement and mRNA therapies and explores the targeted delivery of these payloads using Evox\\\’s proprietary exosome technology Partnership encompasses up to five rare disease targets, including Evox\\\’s Niemann-Pick Type C programme, with Takeda assuming responsibility for its clinical development Evox Therapeutics Ltd (\\\’Evox\\\’ or the \\\’Company\\\’), a leading exosome
Evox Therapeutics and Takeda Sign Multi-target Rare Disease Collaboration Read More »